New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma

Katelyn T. Byrne; Mary Jo Turk

doi:10.18632/oncotarget.323

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma

Katelyn T. Byrne and Mary Jo Turk _

PDF | HTML | How to cite

Oncotarget. 2011; 2:684-694. https://doi.org/10.18632/oncotarget.323

Metrics: PDF 3378 views | HTML 5871 views | ?

Abstract

Katelyn T. Byrne and Mary Jo Turk

¹Dartmouth Medical School and the Norris Cotton Cancer Center, Lebanon, NH, USA

Received: September 7, 2011; Accepted: September 9, 2011; Published: September 10, 2011;

Keywords: melanoma, vitiligo, melanocytes, CD8 T cells, CD4 T cells, T cell memory

Correspondence:

Mary Jo Turk, email:

Abstract

Melanoma-associated vitiligo is the best-studied example of the linkage between tumor immunity and autoimmunity. Although vitiligo is an independent positive prognostic factor for melanoma patients, the autoimmune destruction of melanocytes was long thought to be merely a side effect of robust anti-tumor immunity. However, new data reveal a key role for vitiligo in supporting T cell responses to melanoma. This research perspective reviews the history of melanoma-associated vitiligo in patients, the experimental studies that form the basis for understanding this relationship, and the unique characteristics of melanoma-specific CD8 T cells found in hosts with vitiligo. We also discuss the implications of our recent findings for the interpretation of patient responses, and the design of next-generation cancer immunotherapies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 323

Publication Alerts

Research Perspectives:

New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma

Abstract